Grass pollen immunotherapy induces Foxp3-expressing CD4+CD25+ cells in the nasal mucosa - 15/08/11
Reprint requests: Kayhan T. Nouri-Aria, PhD, Allergy and Clinical Immunology, National Heart and Lung Institute at Imperial College London, Sir Alexander Fleming Building, London SW7 2AZ, United Kingdom.Abstract |
Background |
Regulatory T (Treg) cells play an important role in controlling allergic inflammation. The transcription factor Foxp3 regulates the development and function of natural and adaptive CD4+CD25+ Treg cells.
Objectives |
We sought to examine the effect of grass pollen injection immunotherapy on the numbers of Foxp3+CD4+ and Foxp3+CD25+ T cells in and out of season and their expression of IL-10 in the nasal mucosa of patients with hay fever.
Methods |
Nasal biopsy specimens were obtained from untreated patients with hay fever, participants with grass pollen allergy who had received 2 years of immunotherapy, and healthy control subjects. Dual-immunofluorescence microscopy was used to enumerate and colocalize Foxp3 expression to CD4+ and CD25+ T cells in the nasal mucosa. Triple staining was performed to colocalize Foxp3+ cells to CD3+CD25+ and CD3+ IL-10–expressing cells.
Results |
At peak season, numbers of Foxp3+CD25+ (P = .02) and Foxp3+CD4+ (P = .03) cells were significantly increased in the nasal mucosa of immunotherapy-treated patients compared with numbers before treatment. Foxp3+CD25+ (P = .03) and Foxp3+CD4+ (P = .04) cells were also greater in immunotherapy-treated patients out of season compared with those in untreated patients with hay fever. Within the immunotherapy-treated group, 20% of CD3+CD25+ cells expressed Foxp3, and 18% of Foxp3+CD3+ cells were IL-10 positive.
Conclusion |
The presence of local Foxp3+CD25+CD3+ cells in the nasal mucosa, their increased numbers after immunotherapy, and their association with clinical efficacy and suppression of seasonal allergic inflammation support a putative role for Treg cells in the induction of allergen-specific tolerance in human subjects.
Le texte complet de cet article est disponible en PDF.Key words : Foxp3, CD4+CD25+ Treg cells, IL-10, grass pollen immunotherapy, hay fever/allergic rhinitis
Abbreviations used : GP-IT, IQR, Treg
Plan
| Funding for this project was from the Medical Research Council UK. K.T.N.-A. was supported by the Advanced Drug Discovery Initiative, a collaborative project between Imperial College Trust and GlaxoSmithKline. ALK-Abelló, Hørsholm, Denmark, supported the clinical trial of grass pollen subcutaneous immunotherapy. |
|
| Disclosure of potential conflict of interest: S. R. Durham has consulting arrangements with ALK-Abelló; has received research support from ALK-Abelló; is partially funded by the Immune Tolerance Network of the National Institutes of Health; and is on the speakers’ bureau for ALK-Abelló, Allergy Therapeutics, and Stallergenes. The rest of the authors have declared that they have no conflict of interest. |
Vol 121 - N° 6
P. 1467 - juin 2008 Retour au numéro
Article précédent
- Children with egg allergy have evidence of reduced neonatal CD4+CD25+CD127lo/− regulatory T cell function
- Miranda Smith, Michelle R. Tourigny, Paul Noakes, Catherine A. Thornton, Meri K. Tulic, Susan L. Prescott
- Anti–IL-5 (mepolizumab) therapy reduces eosinophil activation ex vivo and increases IL-5 and IL-5 receptor levels
- Miguel L. Stein, Joyce M. Villanueva, Bridget K. Buckmeier, Yoshiyuki Yamada, Alexandra H. Filipovich, Amal H. Assa’ad, Marc E. Rothenberg
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?